JP2014523238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523238A5 JP2014523238A5 JP2014515209A JP2014515209A JP2014523238A5 JP 2014523238 A5 JP2014523238 A5 JP 2014523238A5 JP 2014515209 A JP2014515209 A JP 2014515209A JP 2014515209 A JP2014515209 A JP 2014515209A JP 2014523238 A5 JP2014523238 A5 JP 2014523238A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- modified
- ubiquitin
- sequence number
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims 21
- 102000037865 fusion proteins Human genes 0.000 claims 21
- 102000044159 Ubiquitin Human genes 0.000 claims 20
- 108090000848 Ubiquitin Proteins 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000000178 monomer Substances 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108090000467 Interferon-beta Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000008300 Mutant Proteins Human genes 0.000 claims 2
- 108010021466 Mutant Proteins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000009870 specific binding Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 102000035118 modified proteins Human genes 0.000 claims 1
- 108091005573 modified proteins Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/002962 WO2012171541A1 (en) | 2011-06-15 | 2011-06-15 | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
| EPPCT/EP2011/002962 | 2011-06-15 | ||
| PCT/EP2012/061459 WO2012172058A1 (en) | 2011-06-15 | 2012-06-15 | Human fusion proteins comprising interferons and targeted modified ubiquitin proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523238A JP2014523238A (ja) | 2014-09-11 |
| JP2014523238A5 true JP2014523238A5 (enExample) | 2015-03-26 |
Family
ID=46354263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014515209A Pending JP2014523238A (ja) | 2011-06-15 | 2012-06-15 | インターフェロンと標的化修飾ユビキチンタンパク質とを含むヒト融合タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140219959A1 (enExample) |
| JP (1) | JP2014523238A (enExample) |
| AU (1) | AU2012268973A1 (enExample) |
| CA (1) | CA2837875A1 (enExample) |
| IL (1) | IL229723A0 (enExample) |
| WO (2) | WO2012171541A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6146821B2 (ja) | 2011-06-15 | 2017-06-14 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | 修飾ユビキチンに基づく二量体型結合タンパク質 |
| WO2014094799A1 (en) * | 2012-12-19 | 2014-06-26 | Scil-Proteins-Gmbh | Ubiquitin moieties as a means for prolonging serum half-life |
| JP6738340B2 (ja) | 2015-02-06 | 2020-08-12 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | 新規なｅｇｆｒ結合タンパク質 |
| EP3322721B1 (en) | 2015-07-16 | 2021-12-08 | Navigo Proteins Gmbh | Novel immunoglobulin-binding proteins and their use in affinity purification |
| JP2018520675A (ja) | 2015-07-20 | 2018-08-02 | ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ | ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法 |
| AU2017260274A1 (en) | 2016-05-04 | 2018-11-01 | Navigo Proteins Gmbh | Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker |
| JP6951417B2 (ja) | 2016-08-11 | 2021-10-20 | レプリゲン・コーポレイションＲｅｐｌｉｇｅｎ Ｃｏｒｐｏｒａｔｉｏｎ | アフィニティークロマトグラフィーのためのＦＣ−結合タンパク質、並びにＦｃ−結合タンパク質を含むアフィニティー分離マトリックスおよびその使用 |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| EP3706804B1 (en) | 2017-11-07 | 2022-02-23 | Navigo Proteins GmbH | Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer |
| EP4495597A3 (en) | 2018-01-04 | 2025-04-30 | Iconic Therapeutics LLC | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods |
| EP3737703A4 (en) * | 2018-01-11 | 2021-12-08 | UTI Limited Partnership | TREATMENT OF FRAGILE X SYNDROME |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| AU2019409572B2 (en) | 2018-12-18 | 2022-11-24 | Navigo Proteins Gmbh | Novel FOLR1 specific binding proteins for cancer diagnosis and treatment |
| CN113677698B (zh) * | 2019-04-10 | 2025-02-25 | 纳维格蛋白质有限公司 | 用于癌症诊断和治疗的新的psma特异性结合蛋白 |
| JP7457733B2 (ja) | 2019-05-30 | 2024-03-28 | グリットストーン バイオ インコーポレイテッド | 改変アデノウイルス |
| US20220323546A1 (en) * | 2020-04-20 | 2022-10-13 | Altum Pharmaceuticals Inc. | Recombinant interferon |
| WO2021217113A1 (en) * | 2020-04-25 | 2021-10-28 | East Carolina University | Compositions and methods of treating a coronavirus infection by use of an interferon fusion protein |
| EP4192496A4 (en) | 2020-08-06 | 2025-01-01 | Gritstone bio, Inc. | MULTIEPITOP VACCINE CASSETTES |
| WO2022232015A1 (en) * | 2021-04-26 | 2022-11-03 | East Carolina University | Compositions and methods of treating pathogenic infections by using fusion proteins |
| WO2023239213A1 (ko) * | 2022-06-10 | 2023-12-14 | 주식회사 쎌트로이 | 염증세포에서 특이적으로 작동하는 융합단백질 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| ATE526039T1 (de) | 2000-02-24 | 2011-10-15 | Philogen Spa | Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
| CA2400622A1 (en) | 2000-02-24 | 2001-08-30 | Eidgenossische Technische Hochschule Zurich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| DE10360483B4 (de) | 2003-12-22 | 2007-11-15 | Scil Proteins Gmbh | Expressionsvektor und dessen Verwendung |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| ES2341126T3 (es) | 2005-05-11 | 2010-06-15 | Philogen S.P.A. | Proteina de fusion del anticuerpo l19 contra fibronectina ed-b e interleucina 12. |
| CN101356271A (zh) | 2005-11-09 | 2009-01-28 | 拜耳先灵医药股份有限公司 | 功能阻断性抗-ed-b-纤连蛋白抗体的鉴别与鉴定 |
| EP1842553A1 (en) | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
| ES2606490T3 (es) | 2006-05-08 | 2017-03-24 | Philogen S.P.A. | Citocinas dirigidas por anticuerpos para terapia |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| WO2009126558A1 (en) * | 2008-04-10 | 2009-10-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology |
| RU2556820C2 (ru) * | 2009-12-14 | 2015-07-20 | Сцил Протеинс Гмбх | Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина |
-
2011
- 2011-06-15 WO PCT/EP2011/002962 patent/WO2012171541A1/en not_active Ceased
-
2012
- 2012-06-15 JP JP2014515209A patent/JP2014523238A/ja active Pending
- 2012-06-15 AU AU2012268973A patent/AU2012268973A1/en not_active Abandoned
- 2012-06-15 WO PCT/EP2012/061459 patent/WO2012172058A1/en not_active Ceased
- 2012-06-15 CA CA2837875A patent/CA2837875A1/en not_active Abandoned
- 2012-06-15 US US14/126,341 patent/US20140219959A1/en not_active Abandoned
-
2013
- 2013-11-28 IL IL229723A patent/IL229723A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523238A5 (enExample) | ||
| Morales et al. | The antiviral activities of ISG15 | |
| JP2013541335A5 (enExample) | ||
| RU2012114662A (ru) | Модифицированные убиквитиновые белки со специфической связывающей активностью для экстрадомена "в" фибронектина | |
| JP2017160222A5 (enExample) | ||
| JP2010536341A5 (enExample) | ||
| JP2017018125A5 (enExample) | ||
| JP2011525363A5 (enExample) | ||
| HRP20130194T1 (hr) | Imunosupresivni polipeptidi i nukleinske kiseline | |
| RU2011129860A (ru) | Эффективный транспорт в лейкоциты | |
| JP2017529326A5 (enExample) | ||
| JP2014526881A5 (enExample) | ||
| JP2021187828A (ja) | 組換えフィブロネクチン変異体、その調整方法及びその使用 | |
| JP7728755B2 (ja) | 細胞を再プログラム化して形質細胞様樹状細胞またはｉ型インターフェロン産生細胞に変換する組成物、その方法および用途 | |
| JP2018528237A5 (enExample) | ||
| JP2016508143A5 (enExample) | ||
| HRP20120246T1 (hr) | Aktivne varijante il-18 vezujućeg proteina i njihove medicinske upotrebe | |
| JP2005523681A5 (enExample) | ||
| RU2013111675A (ru) | Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc | |
| CN102863537A (zh) | 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用 | |
| KR20240046248A (ko) | 이중특이성 항체 및 이의 응용 | |
| CN104045715A (zh) | 二聚体化融合蛋白的制备及应用 | |
| CN118666961A (zh) | 人白蛋白特异结合多肽及其应用 | |
| RU2003133982A (ru) | Новые полинуклеотиды и полипептиды гена ifn альфа-17 | |
| CN104292337A (zh) | 猪融合干扰素 |